液体活检新技术在临床肿瘤诊疗中的应用新进展

液体活体检查(液体活检)能够非侵入性地反映体内肿瘤状态,为肿瘤的早期诊断、个体化治疗监测以及预后判断提供有力依据。根据肿瘤相关物质的类型,液体活检涵盖了循环肿瘤细胞(CTCs)、循环肿瘤DNA(ctDNA)、细胞外囊泡(EVs)和循环肿瘤RNA(ctRNA)等检测靶标。目前,已有多项液体活检产品获准进入临床,更有许多转化研究蓬勃开展。尽管液体活检技术的临床应用仍然面临着诸多挑战,标准化与质量管理体系还有待完善,但是液体活检作为应用前景广阔的检测新技术,将成为临床迫切需求并值得信赖的诊断工具,为肿瘤检测带来极大便利。

Progress in the application of novel liquid biopsy techniques in clinical tumor diagnosis and treatment

Liquid biopsy can non-invasively reveal the status of tumors in vivo,and provides a powerful basis for early diagnosis,personalized treatment monitoring and prognosis prediction.According to the type of tumor-associated material,liquid biopsy covers circulating tumor cells(CTCs),circulating tumor DNA(ctDNA),extracellular vesicles(EVs)and circulating tumor RNA(ctRNA)etc.At present,several liquid biopsy products havebeen approved for clinical use,while many transformation studies have been vigorously carried out.However,there are still many clinical challenges to be solved effectively.Despite the standardization of detection and quality management system of liquid biopsy are lagged with the rapid development of technology,liquid biopsy,as a highly promising detection technology,will become a reliable diagnostic tool with the increasing clinical requirements for facilitating the tumor management.